Abstract. Osteosarcoma is the most common primary bone tumor that occurs in children and adolescents. Osteosarcoma has a poor prognosis and is often unresponsive to chemotherapy. Therefore, it remains a challenge to identify a novel strategy to effectively treat osteosarcoma. The present study demonstrated a novel opportunity in osteosarcoma treatment using the natural compound plumbagin. Plumbagin reduced cell viability in osteosarcoma cells but not normal bone cells, as determined by MTT assay and colony formation assay. Plumbagin induced cell apoptosis by mitochondrial dysfunction, which in turn promoted Ca 2+ release and endoplasmic reticulum (ER)-stress, as determined by DAPI staining assay, DNA fragmentation assay, flow cytometry and western blotting analysis. In addition, plumbagin improved reactive oxygen species (ROS) generation, as determined by flow cytometry. Finally, these apoptotic cascades activated caspase-3 and caspase-9 to elicit apoptosis response. Our results demonstrated the anticancer effect of plumbagin by inducing cell apoptosis in osteosarcoma cells. In conclusion, plumbagin activated the apoptosis signaling pathway through eliciting ROS, ER stress, mitochondria dysfunction, and finally causing caspase activation. These results indicated that plumbagin may serve as potential antitumor drug by its multifunctional effects in osteosarcoma.
Introduction
Osteosarcoma is the most common primary bone tumor occurring in adolescents. To date, conventional therapies containing chemotherapy and radiation treatment have had a poor response. Moreover, pulmonary metastasis is responsible for the high mortality in osteosarcoma patients (1) . Therefore, it is important to develop an alternative strategy in osteosarcoma treatment. Previously, natural compounds have been implicated in tumor therapy by its antitumor effects to suppress tumor proliferation or induce apoptosis of tumor cells (2) .
Plumbago zeylanica L. (also known as 'Chitrak') is a traditionally used medicinal plant that has numerous biological functions such as anticarcinogenic, antiatherosclerotic and antimicrobial effects (3) (4) (5) . Plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone), a quinonoid constituent isolated from the root of Plumbago zeylanica (Fig. 1A) shows antitumor effects in various tumors, for example breast cancer (6) , cervical cancer (4), prostate cancer (7) and lung cancer (8) . However, little is understood regarding the mechanism of plumbagin-induced antitumor effects in osteosarcoma.
Dysregulation of cell apoptosis, also named 'programmed cell death', is an important characteristic in tumor progression. Numerous natural compounds bring about their antitumor effects by inducing apoptosis in cancer cells (9) . There are two major mechanisms involved in apoptosis regulation. One is the extrinsic pathway, which is elicited by the Fas death receptor, a member of the tumor necrosis factor receptor superfamily (10) . The other is the intrinsic pathway, in which the mitochondria serve a central role by releasing cytochrome c (11) . Finally, these signals activate a series of proteases named caspases. For example, the intrinsic and extrinsic apoptotic pathways activate caspase-3 and lead to DNA condensation and fragmentation (12) . Previously, ROS have also been implicated in apoptosis induction through the activation of the mitochondrial-dependent cell death pathway (13) . Discovery of mechanisms involved in apoptosis provides an opportunity for novel targeted therapies that promote death in cancer cells.
In the present study, the authors reported the antitumor effect of plumbagin in osteosarcoma cells. The results indicated that plumbagin induces cell apoptosis by inducing the ROS-related mitochondria-dependent cell death pathway of human osteosarcoma cells.
Materials and methods

Materials.
Horseradish peroxidase-conjugated anti-mouse and anti-rabbit IgG, and rabbit polyclonal antibodies specific for β-actin (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany; cat. no. SI-A5441; 1:10,000), voltage-dependent anion channel (GeneTex International Corporation, Hsinchu, Taiwan; cat. no. GTX-104745; 1:1,000), cytochrome c (GeneTex International Corporation; cat. no. GTX-108580; 1:1,000), B cell lymphoma (Bcl)-2 (GeneTex International Corporation; cat. no. GTX-100064; 1:1,000), Bcl-xL (GeneTex International Corporation; cat. no. GTX-105661; 1:1,000), Bcl-2-associated X (Bax; GeneTex International Corporation; cat. no. GTX-109683; 1:1,000), Bcl-2 homologous antagonist/killer (Bak; GeneTex International Corporation; cat. no. GTX-100063; 1:1,000), 78 kDa glucose-regulated protein (GRP78) (GeneTex International Corporation; cat. no. GTX113340; 1:1,000), GRP94 (GeneTex International Corporation; cat. no. GTX103203; 1:1,000), caspase-3 (Santa Cruz Biotechnology, Inc., Dallas, TX, USA; cat. no. SC-7272; 1:1,000), caspase-9 (Santa Cruz Biotechnology, Inc.; cat. no. SC-56073; 1:1,000) and poly (ADP-ribose) polymerase (PARP; GeneTex International Corporation; cat. no. GTX100573, 1:1,000) were used in the present study. Plumbagin from Plumbago indica and all other chemicals were obtained from Sigma-Aldrich; Merck KGaA.
Cell culture. The human osteosarcoma cell lines (MG-63, U2OS, HOS) and osteoblast cell line (hFOB 1.19) were purchased from American Type Culture Collection (Manassas, VA, USA). MG-63, U2OS, HOS and hFOB 1.19 cells were maintained in an α-modified Eagle's medium (MEM), McCoy's 5A, α-MEM and DMEM/Ham's F-12 medium, respectively (all Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). All cells were incubated at 37˚C in an atmosphere of 5% CO 2 supplemented with 20 mM hydroxyethyl piperazineethanesulfonic acid (HEPES; Sigma-Aldrich; Merck KGaA), 10% heat-inactivated fetal calf serum (FBS), 2 mM of glutamine, 100 U/ml penicillin and 100 µg/ml of streptomycin (all Invitrogen; Thermo Fisher Scientific, Inc.). The media were changed every 48 h.
Cell viability assay. Cell viability was determined by MTT assay. Following treatment with indicated condition of plumbagin for 1 or 2 days, cultures were washed with PBS. All cells were incubated with MTT (0.5 mg/ml) for 2 h at 37˚C. Following incubation, dimethylsulfoxide was added to dissolve formazan crystals and shaken at room temperature for 10 min. Finally, the cell viability was assessed by the absorbance of 570 nm using a microplate reader (Bio-Tek Instruments, Winooski, VT, USA).
Colony formation assay. The cells were seeded in six-well plates (1x10 3 cells/well) and incubated with indicated condition of plumbagin (1, 2.5, 5 and 10 µM) for 10 days. Culture media were changed every 2 days. At 10 days, colonies were washed with PBS, fixed for 15 min with 4% paraformaldehyde and stained with 0.1% crystal violet for 5 min. The colony forming cells were photographed. Following undergoing three washes with ddH 2 O, acetic acid was added to a final concentration of 33% (v/v), which was achieved followed by measuring the absorbance at 550 nm. The colony formation assay was repeated three times with duplicate wells.
DAPI staining. The cells were treated with indicated condition of plumbagin for 48 h, the cells were washed with PBS, fixed in a 3.7% formaldehyde solution for 10 min, and stained with DAPI (0.5 µg/ml) for 5 min. The cells were photographed using fluorescence microscopy.
DNA ladder assay. The cells were treated with previously indicated conditions of plumbagin for 48 h. Total DNA were extracted and used to agarose electrophoresis (1.5% agarose gel). The agarose gel was stained with ethidium bromide to assess the DNA fragmentation. Ultraviolet spectroscopy at 302 nm was used to report results.
Western blot analysis. Total cell lysates were extracted as described previously (14) . Proteins were resolved on a 10-15% SDS-PAGE and transferred to polyvinylidene membranes. The blots were blocked with 4% bovine serum albumin (cat. no. A9647; Sigma-Aldrich; Merck KGaA), for 1 h at room temperature and then probed with first antibodies (1:1,000) for 1 h at room temperature. Following three washes, the blots were subsequently incubated with peroxidase-conjugated secondary antibodies (1:1,000) for 1 h at room temperature. The blots were visualized by enhanced chemiluminescence using Kodak X-OMAT LS film (Kodak, Rochester, NY, USA). The bands were analyzed using ImageJ software (version 1.51k; https://imagej.nih.gov/ij/). Each experiment was repeated at least three times.
Annexin V/propidium iodide (PI) staining. Apoptosis was assessed using Annexin V, a protein that binds to phosphatidylserine residues which are exposed on the cell surface of apoptotic cells, as previously described (15) . Cells (2x10 6 cells) were treated with indicated conditions of plumbagin. Following treatment, cells were washed twice with PBS, and resuspended in staining buffer containing 1 µg/ml PI and 0.025 µg/ml annexin V-fluorescein isothiocyanate (FITC). Double-labeling was performed at room temperature for 10 min in the dark prior to flow cytometric analysis. Cells were immediately analyzed using FACScan and the CellQuest pro software (version 5.1; BD Biosciences, Franklin Lakes, NJ, USA).
Cell cycle analysis by PI staining. Quantitative assessment of apoptotic cells was also assessed by examining the cell cycle. Cells were collected by centrifugation (10 min at 950 x g and 4˚C) and adjusted to 2x10 6 cells/ml. Pre-chilled ethanol was added to 0.5 ml cell suspension and the mixture was incubated at 4˚C for 30 min. Ethanol was then removed by centrifugation (15 min at 1,425 x g and 4˚C), and cellular DNA was stained with 100 µg/ml PI (in PBS containing 0.1% Triton-X 100, and 1 mM EDTA) in the presence of an equal volume of DNase-free RNase A (200 µg/ml; Sigma-Aldrich; Merck KGaA). Following staining, cells were analyzed immediately with FACScan and CellQuest programs (version 5.1; BD Biosciences). The extent of apoptosis was determined by measuring the DNA content of cells below sub G1 peak (16) .
Terminal deoxynucleotidyl-transferase-mediated dUTP nick end labeling (TUNEL) assay.
Quantitative assessment of apoptotic cells was also assessed by TUNEL assay, which examines DNA-strand breaks during apoptosis by using the BD APO-DIRECT™ kit (BD Biosciences; cat. no. 556381). Briefly, cells (2x10 6 cells) were incubated with plumbagin for the indicated times. The cells were trypsinized and collected by centrifugation (10 min at 950 x g and 4˚C). The cells were fixed with 1% paraformaldehyde for 30 min on ice. Once the fixative was removed, cells were washed twice with PBS, ethanol was added to the 0.5 ml cell suspension and the mixture was incubated at -20˚C for 2 h. Ethanol was then removed by centrifugation (15 min at 1,425 x g and 4˚C) and cellular DNA was stained with TUNEL solution (3 ng/µl TdT enzyme and 0.04 nMol FITC dUTP) for 1 h at 37˚C. Following incubation, 1 ml Rinse buffer was added and centrifuged again for 15 min at 1,425 x g and 4˚C. The fluorescein labels incorporated in DNA strand breaks were detected and quantified immediately with FACScan and CellQuest programs (version 5.1; BD Biosciences) with a minimum of 10,000 counts/sample.
Determination of mitochondrial membrane potential.
The mitochondrial membrane potential (ΔΨm) was assessed using the fluorometric probe Tetraethylbenzimidazolylcarbocyanine iodide (JC-1; EMD Millipore, Billerica, MA, USA), a positively charged mitochondria-specific fluorophore that indicates depolarization by a fluorescence emission shift from green (525 nm) to red (610 nm) (17) . Briefly, cells (2x10 6 cells) were plated in six-well culture dishes, grown to confluence, and treated with vehicle or plumbagin. Following incubation, cells were stained with JC-1 (5 µg/ml) for 15 min at 37˚C and then analyzed by FACScan using an argon laser (488 nm). Mitochondrial depolarization, which is specifically indicated by a decrease in the red/green fluorescence intensity ratio, was analyzed by CellQuest program (version 5.1; BD Biosciences).
Measurements of reactive oxygen species. Levels of intracellular H 2 O 2 were assessed spectrofluorimetrically by oxidation of specific probes: H 2 DCFDA (Molecular Probes; Thermo Fisher Scientific, Inc.). Cells were plated at a density of 5x10 5 , allowed to attach overnight, and exposed to plumbagin for specified time intervals. The cells were stained with H 2 DCFDA (10 µM) for 10 min at 37˚C and the fluorescence intensity in cells was determined using the flow cytometry. The levels of ROS generation was stained with CellROX ® Deep Red reagent (Thermo Fisher Scientific, Inc.), and ROS generation was assessed by using the flow cytometry.
Detection of Ca 2+ Concentrations. Cells (2x10 5 ) seeded in 12-well plates were incubated with plumbagin for indicated times to detect changes in Ca 2+ levels. Cells were harvested and washed twice, and re-suspension in Fluo 3/AM (3 µg/ml; Sigma-Aldrich; Merck KGaA) at 37˚C for 30 min and analyzed by flow cytometry. For Ca 2+ expression, the cells were stained with Calcium Assay kit (Cayman Chemical Company, Ann Arbor, MI, USA) and Ca 2+ expression was assessed by using flow cytometry.
Caspase activity assay. The assay is based on the ability of the active enzyme to cleave the chromophore from the enzyme substrate Ac-LEHD-pNA (for caspase-9; cat. no. APT173; EMD Millipore) and Ac-DEVD-pNA (for caspase-3; cat. no. APT131; EMD Millipore). The cell lysates were prepared and incubated with the specific anti-caspase-9 and caspase-3 substrate solution (final substrate concentration of 0.3 mg/ml) for 2 h at 37˚C. The release of p-nitroaniline was monitored at 405 nm. Results are represented as the percentage change of the activity compared to the untreated control.
Migration and invasion assay. The upper chambers were coated with BD Matrigel Basement Membrane Matrix (50 µg/ml; BD Biosciences). Cells (1x10 4 ) in serum-free medium were added to the upper chamber of a Transwell insert, and vehicle control or plumbagin (1, 2.5, 5 and 10 µM) in serum-free medium was applied to the lower chamber, followed by incubation. At 18 h, cells were fixed with 3.7% formaldehyde and stained with 0.05% crystal violet. Stained cells that migrated to the lower chamber were counted.
Statistical analysis. Data are presented as the mean ± standard error of the mean. Statistical comparisons between two groups were performed using the Student's t test. P<0.05 was conside red to indicate a statistically significant difference. 
Results
Plumbagin triggers cell apoptosis in human osteosarcoma cells. The authors first examined whether plumbagin could trigger apoptosis in osteosarcoma cells. Osteosarcoma cells (MG63, U2OS, HOS and hFOB1.19) were incubated with plumbagin for 24 or 48 h, and the results indicated that plumbagin reduced cell viability in osteosarcoma cells but not normal bone cells (Fig. 1B) . The IC 50 values at 48 h of plumbagin were 0.59, 0.78 and 1.24 µM for MG63, HOS and U2OS cells, respectively. The colony formation assay also consolidated the antitumor effect of plumbagin in osteosarcoma cells (Fig. 1C) . Therefore, the authors investigated whether plumbagin induces apoptosis in osteosarcoma cells. The results indicated that plumbagin obviously increased DNA condensation (Fig. 1D) . Degradation of chromatin was detected by a DNA ladder assay following plumbagin treatment ( Fig. 2A) . Cell apoptosis was also confirmed by cell cycle, Annexin V/PI double-labeling and TUNEL assay (Figs. 2B and C) . To further verify the apoptosis induced by plumbagin, DNA fragmentation was conducted, as it is an important marker of apoptosis. It was observed that plumbagin induced cell apoptosis characteri zed by marked DNA fragmentation (Fig. 2D) . These results support that plumbagin induces cell apoptosis in osteosarcoma cells.
ROS-triggered mitochondrial dysfunction is involved in plumbagin-induced apoptosis in osteosarcoma cells.
ROS is known to induce mitochondrial dysfunction which promotes mitochondrial apoptotic pathway (18) . Reactive oxygen species accumulation was detected after plumbagin treatment. The results demonstrated that H 2 O 2 and ROS accumulation were increased following plumbagin treatment ( Fig. 3A and B) . Moreover, plumbagin-induced apoptosis was reversed by pretreating with ROS scavenger N-acetyl cysteine (NAC), NADPH oxidase inhibitor diphenyleneiodonium chloride (DPI) and H 2 O 2 scavenging enzyme (catalase) (Fig. 3C  and D) . JC-1 is a cationic dye that accumulates in energized mitochondria. In healthy cells, JC-1 accumulated as aggregates in the mitochondrial membranes, presenting a red to orange fluorescence. In unhealthy cells, a monomer that yields green fluorescence was shown. Treatment of cells with plumbagin induced marked changes in mitochondrial membrane proteins, as demonstrated by the disappearance of orange-red fluorescence, or by the increase of green fluorescence (Fig. 3E) . The increase of the proapoptotic/antiapoptotic Bcl-2 ratio and release of cytochrome c confirmed that the mitochondrial apoptosis pathway was induced by plumbagin treatment (Fig. 3F-K) . In summary, these results suggested that plumbagin induces cell apoptosis through the ROS-triggered mitochondrial apoptotic pathway in osteosarcoma cells.
Endoplasmic reticulum (ER) stress is involved in plumbagin-induces apoptosis in human osteosarcoma cells.
A previous study indicated that ER stress-related events are correlated with ROS generation such as unfolded protein response (19) . Since Ca 2+ release is highly associated with ER stress-related mitochondria dysfunction (20) , the authors therefore examined Ca 2+ accumulation following plumbagin incubation. The results demonstrated that plumbagin treatment increased intracellular calcium concentration ( Fig. 4A and B) . The results also indicated that GRP78 and GRP94, two major components involved in ER stress, were upregulated by plumbagin incubation (Fig. 4C and D) . The authors confirmed this suggestion by pretreatment cell with cell-permeant chelator of calcium (BAPTA-AM), and the data showed that plumbagin-induced apoptosis was inhibited by pretreatment with BAPTA-AM (Fig. 4E and F) . Conclusively, these data indicated that plumbagin induces apoptosis through the ER-stress pathway.
Plumbagin induced caspases activation in human osteosarcoma cells. Caspases are the critical components that regulate the apoptotic response. Finally, caspases activation was assessed following plumbagin incubation. Results indicated that caspase-3, caspase-9 and PARP (a downstream effector of caspase-3) were activated following plumbagin incubation ( Fig. 5A and B) . Plumbagin also increased caspase-3 and caspase-9 activity in osteosarcoma cells ( Fig. 5C and D) . Finally, pretreatment with caspase inhibitors abolished plumbagin induced cell apoptosis ( Fig. 5E and F) . These results suggested that caspase activation participates in plumbagin-induced cell apoptosis in osteosarcoma (Fig. 5G) .
Discussion
Osteosarcoma is the most common bone malignancy that occurs in children. To date, chemotherapy and surgery are the only conventional treatment strategies. However, multidrug resistance limits the efficacy of chemotherapy in osteosarcoma and the 5-year survival rate is ~20%. Therefore, developing novel therapeutic strategies and improving prognosis is necessary. In the current study, the authors provide a new opportunity by using the natural product plumbagin in osteosarcoma therapy. Plumbagin induced cell apoptosis through activating ROS, ER stress, mitochondria dysfunction and caspase activation. In summary, the present study indicated that plumbagin may be a potential anticancer drug in osteosarcoma treatment.
Recently, the use of natural compounds in cancer therapy has become an alternative option. Plumbagin, the extract compound isolated from plants, has diverse biological functions such as antioxidant, anti-inflammatory, anti-bacterial and anticancer properties (21) . Plumbagin demonstrates anticancer effects through various mechanisms. For example, plumbagin induces G2-M cell cycle arrest and autophagy of human breast cancer cells by targeting the Akt/mTOR pathway (6) . In prostate cancer, plumbagin induces apoptosis through ROS generation and depletion of intracellular GSH levels. The authors reported that plumbagin-induced apoptosis was regulated by ROS generation. In addition, they indicated that plumbagin activated the mitochondrial apoptotic pathway, which, in turn, promoted the cleavage of caspase-9, caspase-3 and PARP. These investigations are in agreement with previous studies in lung cancer and pancreatic cancer (22, 23) . Interestingly, the current finding indicated that plumbagin induced-apoptosis is correlated with ER-stress in osteosarcoma, and this effect has never been discussed before, to the best of the authors' knowledge.
Plumbagin demonstrates its anti-metastatic effects through migration and invasion inhibition in breast cancer (24) . Moreover, plumbagin inhibits osteolytic bone metastasis by modulating the tumor-bone microenvironment in breast cancer (25, 26) . However, little is understood about the anti-metastatic function of plumbagin in cancer progression. Recently, the bone microenvironment has been implicated in osteosarcoma progression. The interaction between osteosarcoma cells and resident cells such as osteoblasts, chondrocytes, mesenchymal stem/progenitor cells, hematopoietic cells and endothelial cells serve a central role in osteosarcoma progression (27) . The role of plumbagin in osteosarcoma progression by modulating the bone microenvironment will be discussed in the future.
The conventional treatment strategy for osteosarcoma still leaves a poor prognosis. The present study reported the anticancer effect of plumbagin by inducing apoptosis in osteosarcoma cells. Plumbagin shows anticancer effects through multiple mechanisms in various tumors. These findings provide a novel insight into the action of plumbagin in osteosarcoma.
The antitumor effect of plumbagin was conducted by modulating multiple mechanisms in osteosarcoma. Plumbagin activated the apoptosis signaling pathway through eliciting ROS, ER stress, mitochondria dysfunction and causing caspase activation. In conclusion, these results indicated that plumbagin may serve as a potential antitumor drug by its multifunctional effects in osteosarcoma.
